-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec.
Two patients with advanced Hodgkin's lymphoma developed resistance to all therapies.
The doctor told them that hospice care might be their last choice.
However, after participating in a clinical trial and receiving an innovative immunotherapy treatment called "natural killer" (NK), the two patients achieved complete remission.
Today, the results of this clinical trial were announced at the American Association for Cancer Research (AACR) annual meeting.
Researchers said that although the research is still in its early stages, it demonstrates the potential of using natural killer cells to treat cancer.
Natural killer cells are the innate immune cells that exist in the human body.
Like common T cells, they have the ability to attack tumor cells, but the mechanism of killing tumor cells is different.
On the basis of the successful treatment of blood diseases by CAR-T therapy, many biomedical companies are also developing and using natural killer cells to treat cancer.
At present, most companies adopt the method to develop CAR-NK cells, which is to integrate antigen chimeric receptors ( CAR) is expressed on NK cells, allowing them to target tumor cells.
The NK cell therapy used in this clinical trial is a different approach.
It comes from Affimed.
The company's strategy is to combine natural killer cells that do not have the ability to target with the innate cell engager (ICE) that gives the cells the ability to target.
Part of this compound can bind to CD16A on the surface of NK cells and macrophages, which can activate these cells without the need for costimulatory signals.
Another part of it can bind to specific antigens on the surface of tumor cells, thereby recruiting NK cells and macrophages to the vicinity of tumor cells and activating them to produce killing effects.
One advantage of this ICE molecule is that it can be "tailored" to target different tumor targets, thereby giving NK cells the ability to treat different cancer types.
▲The mode of action of the combination of the innate cell binder and NK cells (picture source: Affimed official website) In this open-label, phase 1 clinical trial, a total of 4 patients received treatment with NK cells combined with the innate cell binder AFM13 .
AFM13 is an innate cell adaptor that specifically binds to the CD30 antigen on the surface of lymphoma cells.
All patients receiving treatment achieved remission, and two of them achieved complete remission.
It is worth mentioning that the two patients who have achieved complete remission have received 5 and 9 different pre-treatments and developed resistance to them, and they are very difficult to treat.
In terms of safety, the researchers did not observe cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
▲The status and treatment results of the 4 patients who received treatment (picture source: Reference [1]) "The preliminary safety and efficacy data of the first human study gave us great encouragement.
We got 100 out of the first four patients enrolled in the group.
The% remission rate is impressive.
"Affimed’s Chief Medical Officer, Dr.
Andreas Harstrick, said, "These preliminary results show that AFM13 can help NK cells target and destroy cancer cells.
We will continue to use the unique capabilities of the innate cell adaptor.
Combined with NK cell therapy, it provides innovative treatment options for different blood cancers and solid tumors. "Reference: [1] Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13.
Retrieved April 9, 2021, from .
com/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell -engager-afm13/[2] Actualizing the Untapped Potential of the Innate Immune System.
Retrieved April 9, 2021, from Note: The purpose of this article The introduction of medical and health research progress is not a treatment plan recommendation.
If you need treatment plan guidance, please go to a regular hospital for treatment.
Two patients with advanced Hodgkin's lymphoma developed resistance to all therapies.
The doctor told them that hospice care might be their last choice.
However, after participating in a clinical trial and receiving an innovative immunotherapy treatment called "natural killer" (NK), the two patients achieved complete remission.
Today, the results of this clinical trial were announced at the American Association for Cancer Research (AACR) annual meeting.
Researchers said that although the research is still in its early stages, it demonstrates the potential of using natural killer cells to treat cancer.
Natural killer cells are the innate immune cells that exist in the human body.
Like common T cells, they have the ability to attack tumor cells, but the mechanism of killing tumor cells is different.
On the basis of the successful treatment of blood diseases by CAR-T therapy, many biomedical companies are also developing and using natural killer cells to treat cancer.
At present, most companies adopt the method to develop CAR-NK cells, which is to integrate antigen chimeric receptors ( CAR) is expressed on NK cells, allowing them to target tumor cells.
The NK cell therapy used in this clinical trial is a different approach.
It comes from Affimed.
The company's strategy is to combine natural killer cells that do not have the ability to target with the innate cell engager (ICE) that gives the cells the ability to target.
Part of this compound can bind to CD16A on the surface of NK cells and macrophages, which can activate these cells without the need for costimulatory signals.
Another part of it can bind to specific antigens on the surface of tumor cells, thereby recruiting NK cells and macrophages to the vicinity of tumor cells and activating them to produce killing effects.
One advantage of this ICE molecule is that it can be "tailored" to target different tumor targets, thereby giving NK cells the ability to treat different cancer types.
▲The mode of action of the combination of the innate cell binder and NK cells (picture source: Affimed official website) In this open-label, phase 1 clinical trial, a total of 4 patients received treatment with NK cells combined with the innate cell binder AFM13 .
AFM13 is an innate cell adaptor that specifically binds to the CD30 antigen on the surface of lymphoma cells.
All patients receiving treatment achieved remission, and two of them achieved complete remission.
It is worth mentioning that the two patients who have achieved complete remission have received 5 and 9 different pre-treatments and developed resistance to them, and they are very difficult to treat.
In terms of safety, the researchers did not observe cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
▲The status and treatment results of the 4 patients who received treatment (picture source: Reference [1]) "The preliminary safety and efficacy data of the first human study gave us great encouragement.
We got 100 out of the first four patients enrolled in the group.
The% remission rate is impressive.
"Affimed’s Chief Medical Officer, Dr.
Andreas Harstrick, said, "These preliminary results show that AFM13 can help NK cells target and destroy cancer cells.
We will continue to use the unique capabilities of the innate cell adaptor.
Combined with NK cell therapy, it provides innovative treatment options for different blood cancers and solid tumors. "Reference: [1] Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13.
Retrieved April 9, 2021, from .
com/affimed-announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell -engager-afm13/[2] Actualizing the Untapped Potential of the Innate Immune System.
Retrieved April 9, 2021, from Note: The purpose of this article The introduction of medical and health research progress is not a treatment plan recommendation.
If you need treatment plan guidance, please go to a regular hospital for treatment.
